Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab.

Talamonti M, D'Adamio S, Galluccio T, Andreani M, Pastorino R, Egan CG, Bianchi L, Galluzzo M.

J Eur Acad Dermatol Venereol. 2019 May 8. doi: 10.1111/jdv.15659. [Epub ahead of print] No abstract available.

PMID:
31066090
2.

Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort.

Bianchi L, Caposiena Caro RD, Ganzetti G, Molinelli E, Dini V, Oranges T, Romanelli M, Fabbrocini G, Monfrecola G, Napolitano M, Egan CG, Musumeci ML, Lacarrubba F, Micali G, Passoni E, Calzavara-Pinton PG, Venturini M, Zanca A, Offidani AM.

Clin Exp Dermatol. 2019 Jul;44(5):e177-e180. doi: 10.1111/ced.13861. Epub 2018 Dec 28.

PMID:
30593710
3.

Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement.

Marchesoni A, D'Angelo S, Anzidei M, Bortolotti R, Cantini F, Caramella D, Carotti M, Chimenti MS, Delle Sedie A, Egan CG, Fabbroni M, Frediani B, Fusaro E, Galeazzi M, Gallazzi MB, Gentileschi S, Gentili F, Gerli R, Gilio M, Iannone F, La Paglia E, Lubrano E, Macarini L, Olivieri I, Pellerito R, Ramonda R, Salvarani C, Scarano E, Scarpa R, Spaggiari L, Spanò A, Zawaideh JP, Mazzei MA; SHARE Study Group.

Clin Exp Rheumatol. 2018 Nov 16. [Epub ahead of print]

PMID:
30557127
4.

Comparison of clinical and ultrasound scores in patients with hidradenitis suppurativa: results from an Italian ultrasound working group.

Napolitano M, Calzavara-Pinton PG, Zanca A, Bianchi L, Caposiena Caro RD, Offidani AM, Ganzetti G, Molinelli E, Dini V, Oranges T, Romanelli M, Egan CG, Fabbrocini G, Monfrecola G, Lacarrubba F, Musumeci ML, Passoni E, Venturini M, Micali G.

J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e84-e87. doi: 10.1111/jdv.15235. Epub 2018 Sep 25. No abstract available.

PMID:
30176092
5.

Putative endothelial progenitor cells predict long-term mortality in type-2 diabetes.

Egan CG, Fondelli C, Pierantozzi E, Tripepi G, Dotta F, Sorrentino V.

Endocrine. 2018 Oct;62(1):263-266. doi: 10.1007/s12020-018-1695-0. Epub 2018 Jul 30. No abstract available.

PMID:
30062543
6.

Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.

Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan CG, Potenza C, Peris K, Bianchi L.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1737-1744. doi: 10.1111/jdv.15077. Epub 2018 Jun 1.

PMID:
29776016
7.
8.

Use of Amplification Fragment Length Polymorphism to Genotype Pseudomonas stutzeri Strains Following Exposure to Ultraviolet Light A.

Lombardi L, Zoppo M, Rizzato C, Egan CG, Scarpato R, Tavanti A.

Pol J Microbiol. 2017 Mar 30;66(1):107-111. doi: 10.5604/17331331.1234998.

PMID:
29359695
9.

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.

Carrera CG, Dapavo P, Malagoli P, Naldi L, Arancio L, Gaiani F, Egan CG, Di Mercurio M, Cattaneo A.

J Dermatolog Treat. 2018 Aug;29(5):481-486. doi: 10.1080/09546634.2017.1395805. Epub 2017 Nov 10.

PMID:
29058948
10.

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

Talamonti M, Galluzzo M, Zangrilli A, Papoutsaki M, Egan CG, Bavetta M, Tambone S, Fargnoli MC, Bianchi L.

Mol Diagn Ther. 2017 Jun;21(3):295-301. doi: 10.1007/s40291-017-0261-4.

PMID:
28130758
11.

Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis.

Salvarani C, Girolomoni G, Di Lernia V, Gisondi P, Tripepi G, Egan CG, Marchesoni A; DREAM study group.

Semin Arthritis Rheum. 2016 Dec;46(3):305-311. doi: 10.1016/j.semarthrit.2016.06.004. Epub 2016 Jun 21.

PMID:
27470190
12.

Pathophysiology and pharmacological targets of VEGF in diabetic macular edema.

Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R.

Pharmacol Res. 2016 Jan;103:149-57. doi: 10.1016/j.phrs.2015.11.003. Epub 2015 Dec 1. Review.

PMID:
26607863
13.

Clinical, ultrasound, and videodermatoscopy monitoring of psoriatic patients following biological treatment.

Micali G, Lacarrubba F, Santagati C, Egan CG, Nasca MR, Musumeci ML.

Skin Res Technol. 2016 Aug;22(3):341-8. doi: 10.1111/srt.12271. Epub 2015 Oct 9.

PMID:
26450445
14.

Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis.

Migliore A, Bizzi E, Egan CG, Bernardi M, Petrella L.

Ther Clin Risk Manag. 2015 Sep 1;11:1325-35. doi: 10.2147/TCRM.S89678. eCollection 2015.

15.

Epidemiology of Frequently Occurring Skin Diseases in Italian Children from 2006 to 2012: A Retrospective, Population-Based Study.

Cantarutti A, Donà D, Visentin F, Borgia E, Scamarcia A, Cantarutti L, Peruzzi E, Egan CG, Villa M, Giaquinto C; Pedianet.

Pediatr Dermatol. 2015 Sep-Oct;32(5):668-78. doi: 10.1111/pde.12568. Epub 2015 Apr 16.

PMID:
25879514
16.

Epoetin beta for the treatment of chemotherapy-induced anemia: an update.

Galli L, Ricci C, Egan CG.

Onco Targets Ther. 2015 Mar 5;8:583-91. doi: 10.2147/OTT.S77497. eCollection 2015. Review.

17.

A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers.

Lavorini F, Chellini E, Innocenti M, Campi G, Egan CG, Mogavero S, Fontana GA.

Cough. 2014 Dec 24;10(1):7. doi: 10.1186/s12997-014-0007-5. eCollection 2014.

18.

Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.

Chmielewska-Wilkoń D, Reggiardo G, Egan CG.

World J Gastroenterol. 2014 Sep 14;20(34):12283-91. doi: 10.3748/wjg.v20.i34.12283.

19.

Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine.

Savi L, Mogavero S, Egan CG.

Drug Des Devel Ther. 2014 Jul 21;8:983-92. doi: 10.2147/DDDT.S61295. eCollection 2014.

20.

Potential therapeutic use of deferoxamine and mesenchymal stem cells in type-1 diabetes: assembling another piece of the jigsaw, in what is a complex puzzle.

Egan CG.

Expert Opin Biol Ther. 2013 Sep;13(9):1221-4. doi: 10.1517/14712598.2013.804506. Epub 2013 May 26.

PMID:
23706016
21.

Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients).

Morosetti M, Gorini A, Costanzo AM, Cipriani S, Dominijanni S, Egan CG, Zappalà L, di Luzio Paparatti U.

Int J Nephrol Renovasc Dis. 2013;6:27-37. doi: 10.2147/IJNRD.S38405. Epub 2013 Feb 18.

22.

Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients.

Genovese S, Passaro A, Brunetti P, Comaschi M, Cucinotta D; PRISMA study group, Egan CG, Chinea B, Bravi F, Di Pietro C.

J Endocrinol Invest. 2013 Sep;36(8):606-16. doi: 10.3275/8895. Epub 2013 Mar 19.

PMID:
23511244
23.

Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis.

Circelli M, Nicolini G, Egan CG, Cremonesi G.

Int J Gen Med. 2012;5:725-34. doi: 10.2147/IJGM.S35220. Epub 2012 Aug 29.

24.

Use of carvedilol in hypertension: an update.

Leonetti G, Egan CG.

Vasc Health Risk Manag. 2012;8:307-22. doi: 10.2147/VHRM.S31578. Epub 2012 May 18. Review.

25.

Renal status in adult volunteers in central Italy: results from Family Abbott Renal Disease Monitoring Project (FARM) study.

Gorini A, Costanzo AM, Egan CG, di Luzio Paparatti U.

J Nephrol. 2012 Jul-Aug;25(4):523-32. doi: 10.5301/jn.5000027.

PMID:
21956766
26.

Effect of pioglitazone on cardiac sympathovagal modulation in patients with type 2 diabetes.

Gianiorio FE, Casu M, Patrone V, Egan CG, Murialdo G.

Acta Diabetol. 2011 Dec;48(4):283-290. doi: 10.1007/s00592-011-0258-0. Epub 2011 Feb 11.

PMID:
21312045
27.

Role of the fixed-dose combination lercanidipine-enalapril in renal protection.

Egan CG, Pontremoli R.

J Nephrol. 2011 Jul-Aug;24(4):428-37. doi: 10.5301/JN.2011.6271. Review.

PMID:
21279953
28.

Bioavailability of Sandimmun® versus Sandimmun Neoral®: a meta-analysis of published studies.

Colombo D, Egan CG.

Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1177-83.

PMID:
21244766
29.

Levels of circulating CXCR4-positive cells are decreased and negatively correlated with risk factors in cardiac transplant recipients.

Egan CG, Caporali F, Capecchi PL, Lazzerini PE, Pasini FL, Sorrentino V.

Heart Vessels. 2011 May;26(3):258-66. doi: 10.1007/s00380-010-0053-9. Epub 2010 Oct 30.

PMID:
21052687
30.

Mucoactive drugs.

Balsamo R, Lanata L, Egan CG.

Eur Respir Rev. 2010 Jun;19(116):127-33. doi: 10.1183/09059180.00003510. Review.

31.

Use of isoxsuprine hydrochloride as a tocolytic agent in the treatment of preterm labour: a systematic review of previous literature.

Giorgino FL, Egan CG.

Arzneimittelforschung. 2010;60(7):415-20. doi: 10.1055/s-0031-1296305.

PMID:
20712130
32.

Reduced levels of putative endothelial progenitor and CXCR4+ cells in coronary artery disease: kinetics following percutaneous coronary intervention and association with clinical characteristics.

Egan CG, Caporali F, Huqi AF, Zito MC, Focardi M, Mondillo S, Pierli C, Marzilli M, Sorrentino V.

Thromb Haemost. 2009 Jun;101(6):1138-46.

PMID:
19492159
33.

Endothelial progenitor cells and colony-forming units in rheumatoid arthritis: association with clinical characteristics.

Egan CG, Caporali F, Garcia-Gonzalez E, Galeazzi M, Sorrentino V.

Rheumatology (Oxford). 2008 Oct;47(10):1484-8. doi: 10.1093/rheumatology/ken299. Epub 2008 Aug 5.

PMID:
18682413
34.

Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes.

Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V.

Diabetologia. 2008 Jul;51(7):1296-305. doi: 10.1007/s00125-008-0939-6. Epub 2008 Feb 20.

PMID:
18286257
36.

PDGF-induced signaling in proliferating and differentiated vascular smooth muscle: effects of altered intracellular Ca2+ regulation.

Egan CG, Wainwright CL, Wadsworth RM, Nixon GF.

Cardiovasc Res. 2005 Aug 1;67(2):308-16.

PMID:
15885673
38.

Pathophysiology of vascular dysfunction in a rat model of chronic joint inflammation.

Egan CG, Lockhart JC, Ferrell WR.

J Physiol. 2004 Jun 1;557(Pt 2):635-43. Epub 2004 Apr 2.

39.

Pathophysiological basis of acute inflammatory hyperaemia in the rat knee: roles of cyclo-oxygenase-1 and -2.

Egan CG, Lockhart JC, Ferrell WR, Day SM, McLean JS.

J Physiol. 2002 Mar 1;539(Pt 2):579-87.

40.

Expression of constitutive but not inducible cyclooxygenase maintains articular perfusion in the rat knee.

Egan CG, Lockhart JC, McLean JS, Ferrell WR.

Exp Physiol. 2001 Mar;86(2):191-7.

PMID:
11429634
41.

Metacarpophalangeal joints in rheumatoid arthritis: laser Doppler imaging--initial experience.

Ferrell WR, Balint PV, Egan CG, Lockhart JC, Sturrock RD.

Radiology. 2001 Jul;220(1):257-62.

PMID:
11426007

Supplemental Content

Support Center